Poster (OncoLilleDays2022) – Mechanobiological characterization of a 3D in vitro pancreatic ductal adenocarcinoma model and the study of tumor-stroma interaction

Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…

We are happy to give a presentation at ESTIV congress in Barcelona (21-25 November 2022)

Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…

Meet us at ESTIV congress in Barcelona (21-25 November 2022)

We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…

Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™

Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…

Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models

We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…

Feedback of Natacha’s internship about the matrix remodeling in Parkinson’s disease: an in vitro study

This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…

Healthcare or how to find new treatments: History (hasardous), today (inefficient) and future (with BIOMIMESYS®)

In this presentation, Nathalie MAUBON (CEO HCS Pharma), give an overview of drugs discovery, from pre-19th century are, where trials are done on humans, to nowadays where clinical trials are safer but with a dramatic rate of failure. She explains what are the “target base screening” and the “phenotypic screening Read more…